Faslodex Advanced Breast Cancer Local Chinese Study

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study will evaluate the efficacy and safety of Faslodex as secondary-line treatment compared with Arimidex in oestrogen receptor positive postmenopausal advanced breast cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Anastrozole; Estradiol; Fulvestrant

Criteria

Inclusion Criteria:

• Postmenopausal advanced breast cancer with oestrogen receptor positive

• Progression under first-line anti-oestrogen therapy.

Exclusion Criteria:

• Life-threatening metastasis; contraindication to anastrozole

• >2 regimens of hormonotherapy for advanced breast cancer